Madrigal Pharmaceuticals (MDGL) News Today $293.64 +20.85 (+7.64%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASHJanuary 19 at 10:02 AM | seekingalpha.comFY2024 Earnings Forecast for MDGL Issued By HC WainwrightJanuary 19 at 2:13 AM | americanbankingnews.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) General Counsel Sells $75,734.57 in StockJanuary 18 at 6:49 AM | insidertrades.comShannon T. Kelley Sells 277 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) StockMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) General Counsel Shannon T. Kelley sold 277 shares of Madrigal Pharmaceuticals stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $273.41, for a total value of $75,734.57. Following the transaction, the general counsel now owns 7,705 shares of the company's stock, valued at $2,106,624.05. This trade represents a 3.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.January 17 at 10:06 PM | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Robert E. Waltermire Sells 442 SharesMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) VP Robert E. Waltermire sold 442 shares of the stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $273.41, for a total transaction of $120,847.22. Following the completion of the sale, the vice president now directly owns 5,058 shares of the company's stock, valued at approximately $1,382,907.78. This trade represents a 8.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.January 17 at 7:31 PM | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Sells $461,789.49 in StockMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) CMO Rebecca Taub sold 1,689 shares of the firm's stock in a transaction on Friday, January 17th. The stock was sold at an average price of $273.41, for a total transaction of $461,789.49. Following the completion of the sale, the chief marketing officer now owns 457,310 shares in the company, valued at approximately $125,033,127.10. The trade was a 0.37 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.January 17 at 7:31 PM | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Trading Up 7.4% - Should You Buy?Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Up 7.4% - Should You Buy?January 17 at 3:53 PM | marketbeat.comWhy Madrigal Pharmaceuticals Stock Was Plummeting This WeekJanuary 17 at 8:28 AM | fool.comAnalysts Issue Forecasts for MDGL FY2024 EarningsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Analysts at HC Wainwright issued their FY2024 earnings per share estimates for shares of Madrigal Pharmaceuticals in a research report issued on Tuesday, January 14th. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical cJanuary 17 at 6:40 AM | marketbeat.comHennion & Walsh Asset Management Inc. Sells 9,013 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Hennion & Walsh Asset Management Inc. trimmed its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 47.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,904 shares of thJanuary 17 at 5:34 AM | marketbeat.comGoldman Sachs maintains Buy on Madrigal shares as Rezdiffra drives strong patient adoptionJanuary 17 at 1:35 AM | msn.comMadrigal CEO touts 'amazing' sales success of new MASH drug, but stock slumpsJanuary 16, 2025 | bizjournals.comEvercore ISI Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)January 16, 2025 | markets.businessinsider.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Down 14.4% - Here's What HappenedMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Down 14.4% - Time to Sell?January 15, 2025 | marketbeat.comMadrigal Pharmaceuticals’ Strong Market Position and Promising Outlook Drive Buy RatingJanuary 14, 2025 | markets.businessinsider.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $400.00 at HC WainwrightHC Wainwright lifted their price objective on Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the company a "buy" rating in a report on Tuesday.January 14, 2025 | marketbeat.comMadrigal shares fall despite strong salesJanuary 14, 2025 | investing.comStrong Outlook for Madrigal Pharmaceuticals: Buy Rating Affirmed Amid Rezdiffra’s Impressive Growth and Market PenetrationJanuary 14, 2025 | markets.businessinsider.comPositive Outlook and Buy Rating for Madrigal Pharmaceuticals Driven by Strong Rezdiffra Performance and Financial StabilityJanuary 14, 2025 | markets.businessinsider.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Down 14.4% - What's Next?Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 14.4% - Should You Sell?January 13, 2025 | marketbeat.comMadrigal Shares Fall 16% On Preliminary 2024 EarningsJanuary 13, 2025 | marketwatch.comMadrigal Pharmaceuticals sees Q4 Rezdiffra revenue $100M-$103MJanuary 13, 2025 | markets.businessinsider.comMadrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on RezdiffraJanuary 13, 2025 | markets.businessinsider.comWhy Madrigal Pharmaceuticals Stock Is Sinking TodayJanuary 13, 2025 | fool.comMadrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on RezdiffraJanuary 13, 2025 | globenewswire.comMadrigal Pharmaceuticals' (MDGL) "Market Outperform" Rating Reiterated at JMP SecuritiesJanuary 13, 2025 | americanbankingnews.comMadrigal Pharmaceuticals' (MDGL) "Market Outperform" Rating Reaffirmed at JMP SecuritiesJMP Securities reaffirmed a "market outperform" rating and set a $427.00 price target on shares of Madrigal Pharmaceuticals in a research note on Friday.January 10, 2025 | marketbeat.comMadrigal Pharmaceuticals’ Rezdiffra Shows Strong Market Growth and Positive Outlook, Justifying Buy RatingJanuary 10, 2025 | markets.businessinsider.comFast Drug Launch For Madrigal Pharmaceuticals Brings Buyout DiscussionJanuary 9, 2025 | seekingalpha.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) have been given a consensus rating of "Moderate Buy" by the thirteen brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating andJanuary 7, 2025 | marketbeat.comBank of America Securities Remains a Sell on Madrigal Pharmaceuticals (MDGL)January 6, 2025 | markets.businessinsider.comMadrigal Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 4, 2025 | msn.comMadrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2025 | globenewswire.comGeode Capital Management LLC Boosts Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Geode Capital Management LLC boosted its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 1.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 405,655 shares of the biopharmaceutical compaDecember 20, 2024 | marketbeat.comMadrigal Pharmaceuticals' SWOT analysis: rezdiffra launch key to stock's futureDecember 19, 2024 | uk.investing.comWellington Management Group LLP Buys New Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Wellington Management Group LLP purchased a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 9,031 shares of the biopharmaceutDecember 19, 2024 | marketbeat.comNovo Nordisk: A New Boost for GLP-1 Sales on the Horizon (MDGL)Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.December 18, 2024 | marketbeat.comBarclays PLC Raises Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Barclays PLC boosted its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 159.9% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 40,279 shares of the biopharmaceutical company's stock after buying anDecember 18, 2024 | marketbeat.comY Intercept Hong Kong Ltd Acquires Shares of 1,736 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Y Intercept Hong Kong Ltd bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,736 shares of the biopharmaceutical company's stock, valued at approxDecember 17, 2024 | marketbeat.comState Street Corp Has $188.40 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)State Street Corp boosted its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 19.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 887,752 shares of the biopharmaceutical company's stockDecember 13, 2024 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by BrokeragesMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) has been given an average rating of "Moderate Buy" by the thirteen analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assignedDecember 13, 2024 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 9.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional inDecember 12, 2024 | marketbeat.com4,881 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Bought by XTX Topco LtdXTX Topco Ltd bought a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 4,881 shares of the biopharmaceutical company's stock, valuDecember 10, 2024 | marketbeat.comBNP Paribas Financial Markets Has $2.07 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)BNP Paribas Financial Markets increased its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 97.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,767 shares of the biopharmaceutical company's stock after buying an additDecember 7, 2024 | marketbeat.comInsider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells 3,600 Shares of StockDecember 6, 2024 | insidertrades.comThe Manufacturers Life Insurance Company Has $6.36 Million Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)The Manufacturers Life Insurance Company lessened its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 16.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,957 shares of the biopharmaceuDecember 6, 2024 | marketbeat.comMadrigal Pharmaceuticals price target raised to $427 from $415 at JMP SecuritiesDecember 5, 2024 | markets.businessinsider.comRTW Investments LP Acquires 77,825 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)RTW Investments LP boosted its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 4.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,993,687 shares of the biopharmaceutical company'sDecember 5, 2024 | marketbeat.comCinctive Capital Management LP Invests $1.08 Million in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Cinctive Capital Management LP bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,074 shares of theDecember 4, 2024 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Fmr LLCFmr LLC reduced its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 0.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 783,545 shares of the biopharmaceutical company's stock after seDecember 4, 2024 | marketbeat.com Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address MDGL Media Mentions By Week MDGL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDGL News Sentiment▼0.490.44▲Average Medical News Sentiment MDGL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDGL Articles This Week▼278▲MDGL Articles Average Week Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Biogen News Today United Therapeutics News Today Neurocrine Biosciences News Today Incyte News Today BioMarin Pharmaceutical News Today Exact Sciences News Today Exelixis News Today Repligen News Today Halozyme Therapeutics News Today Ionis Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MDGL) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
